Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OPINION STATEMENT: The mainstay of treatment for men with three or fewer non-castrate metastatic lesions outside of the prostate remains morbid palliative androgen deprivation therapy. We believe there is now a significant body of retrospective literature to suggest a survival benefit if these men have radical treatment to their primary tumour alongside 'metastasis-directed therapy' to the metastatic deposits. However, this regimen should be reserved to high-volume centres with quality assurance programmes and excellent outcomes. Patients should be made clear as to the uncertainty of benefit for this multi-site treatment strategy, and we await the publication of randomised controlled trials reporting in the next 5 years.

Original publication

DOI

10.1007/s11864-016-0439-8

Type

Journal article

Journal

Curr Treat Options Oncol

Publication Date

12/2016

Volume

17

Keywords

Oligometastatic, Prostate cancer, Combined Modality Therapy, Disease Management, Humans, Male, Neoplasm Metastasis, Prostatic Neoplasms, Treatment Outcome